1. 020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years. Issue 6 (27th May 2022) Authors: Giovannoni, Gavin; Kappos, Ludwig; Seze, Jerome de; Hauser, Stephen L; Overell, James; Koendgen, Harold; Prajapati, Kalpesh; Manfrini, Marianna; Wang, Qing; Wolinsky, Jerry S Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 93:Issue 6(2022) Page Start: A19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 031 Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years. Issue 6 (27th May 2022) Authors: Schmierer, Klaus; Wolinsky, Jerry S; Brochet, Bruno; Hartung, Hans-Peter; Naismith, Robert; Koendgen, Harold; Manfrini, Marianna; Sauter, Annette; Prajapati, Kalpesh; Kappos, Ludwig Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 93:Issue 6(2022) Page Start: A23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 034 Updated safety analysis of ocrelizumab in multiple sclerosis. Issue 6 (27th May 2022) Authors: Schmierer, Klaus; Hauser, Stephen L; Kappos, Ludwig; Montalban, Xavier; Craveiro, Licinio; Hughes, Richard; Prajapati, Kalpesh; Koendgen, Harold; Pradhan, Ashish; Wolinsky, Jerry S Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 93:Issue 6(2022) Page Start: A24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 177 Updated safety analysis of ocrelizumab in multiple sclerosis. Issue 12 (14th November 2019) Authors: Young, Carolyn; Hauser, Stephen; Kappos, Ludwig; Montalban, Xavier; Hughes, Richard; Koendgen, Harold; McNamara, John; Pradhan, Ashish; Wormser, David; Wolinsky, Jerry Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 90:Issue 12(2019) Page Start: e47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis. Issue 2 (15th March 2023) Authors: Hauser, Stephen L.; Bar-Or, Amit; Weber, Martin S.; Kletzl, Heidemarie; Günther, Andreas; Manfrini, Marianna; Model, Fabian; Mercier, Francois; Petry, Claire; Wing, Qing; Koendgen, Harold; Smith, Terence; Kappos, Ludwig Journal: Neurology Issue: Volume 10:Issue 2(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. (29th September 2020) Authors: Hauser, Stephen L.; Kappos, Ludwig; Arnold, Douglas L.; Bar-Or, Amit; Brochet, Bruno; Naismith, Robert T.; Traboulsee, Anthony; Wolinsky, Jerry S.; Belachew, Shibeshih; Koendgen, Harold; Levesque, Victoria; Manfrini, Marianna; Model, Fabian; Hubeaux, Stanislas; Mehta, Lahar; Montalban, Xavier Journal: Neurology Issue: Volume 95:Number 13(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. (June 2018) Authors: Kappos, Ludwig; Butzkueven, Helmut; Wiendl, Heinz; Spelman, Timothy; Pellegrini, Fabio; Chen, Yi; Dong, Qunming; Koendgen, Harold; Belachew, Shibeshih; Trojano, Maria Journal: Multiple sclerosis Issue: Volume 24:Number 7(2018) Page Start: 963 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Issue 12 (December 2020) Authors: Wolinsky, Jerry S; Arnold, Douglas L; Brochet, Bruno; Hartung, Hans-Peter; Montalban, Xavier; Naismith, Robert T; Manfrini, Marianna; Overell, James; Koendgen, Harold; Sauter, Annette; Bennett, Iain; Hubeaux, Stanislas; Kappos, Ludwig; Hauser, Stephen L Journal: Lancet neurology Issue: Volume 19:Issue 12(2020) Page Start: 998 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. (October 2022) Authors: Arnold, Douglas L; Sprenger, Till; Bar-Or, Amit; Wolinsky, Jerry S; Kappos, Ludwig; Kolind, Shannon; Bonati, Ulrike; Magon, Stefano; van Beek, Johan; Koendgen, Harold; Bortolami, Oscar; Bernasconi, Corrado; Gaetano, Laura; Traboulsee, Anthony Journal: Multiple sclerosis Issue: Volume 28:Number 12(2022) Page Start: 1927 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Issue 11 (November 2017) Authors: Ho, Pei-Ran; Koendgen, Harold; Campbell, Nolan; Haddock, Bill; Richman, Sandra; Chang, Ih Journal: Lancet neurology Issue: Volume 16:Issue 11(2017:Nov.) Page Start: 925 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗